We describe herein a protocol for the production of antigen-specific human monoclonal antibodies (hmAbs). Antibody-secreting cells (ASCs) are isolated from whole blood collected 7 d after vaccination and sorted by flow cytometry into single cell plates. The antibody genes of the ASCs are then amplified by RT-PCR and nested PCR, cloned into expression vectors and transfected into a human cell line. The expressed antibodies can then be purified and assayed for binding and neutralization. This method uses established techniques but is novel in their combination and application. This protocol can be completed with as little as 20 ml of human blood and in as little as 28 d when optimal. Although previous methodologies to produce hmAbs, including B-cell immortalization or phage display, can be used to isolate the rare specific antibody even years after immunization, in comparison, these approaches are inefficient, resulting in few relevant antibodies. Although dependent on having an ongoing immune response, the approach described herein can be used to rapidly generate numerous antigen-specific hmAbs in a short time.
INTRODUCTION
This protocol is derived from strategies developed in our recent study characterizing the human B-cell response to influenza 1 . By this technique, it is possible for a lab experienced with the process to produce milligrams of human monoclonal antibodies (hmAbs) in as little as 28 d. This ability to express and characterize antigenspecific hmAbs is extremely useful for a variety of applications. These range from elucidating the interactions of particular antibodies and antigens to exploring basic B-cell immunology or to producing valuable therapeutics. Because of the wide epitope specificity of the antibodies produced by this method, large numbers of high-affinity antibodies can be produced quickly, yielding panels of diagnostics for rapid antigen screens.
Methods to produce hmAbs HmAbs can be produced by several methods, including immortalization of B cells with Epstein-Barr virus 2, 3 , and the production of B-cell hybridomas 4 , humanization of antibodies from other species 5 , using phage display libraries 6 or generating antibodies recombinantly from isolated single B cells 7, 8 . However, the technique described herein is more suited for the rapid development of a large library of antibodies with a range of specificities against a particular immunogen. In methods requiring immortalized B-cell lines, the extensive subcloning and overall shotgun approach limit the number of useful antibodies that can be produced even over extensive periods of time 9 . Current phage display and related platforms spend extensive amounts of time identifying the few candidate antibodies present and a significant portion of these turn out to be of low affinity 9 . Although phage display technology uses fully human heavy and light chain variable genes, the heavy and light chains are randomly paired in vitro, and so are more likely to induce anaphylactic responses as foreign proteins or to be autoreactive if therapeutic uses are the goal. The mAbs generated by in vitro methods or in other species do not provide a true evaluation of the epitope specificities that humans generate in vivo, limiting the use of these techniques for applications such as epitope discovery and vaccine development or evaluation. These same applications have been hindered by technologies using immortalized B-cell lines because of the relatively few specific antibodies isolated that can be generated. Finally, for potential therapeutic applications, the Fab that is produced by phage display libraries or in other species (mice) must be cloned and fused to a human Fc backbone and expressed in a human cell line. These humanizing techniques represent a significant outlay of time and resources 9 .
Comparison to current methods to produce hmAbs There are limitations to this method that are balanced by the advantages. The other approaches described above (Epstein-Barr virus transformation, phage display, etc.) are memory B-cell-based hmAb technologies that allow a retrospective evaluation of the entire history of previous antigen exposures. This allows mAbs to be isolated even 80 years after exposure to the pathogen as recently illustrated by the cloning of antibodies against the 1918 influenza pandemic strain from a 95-year-old donor 10 . These methods negate the need for obtaining fresh samples (frozen peripheral blood mononuclear cells (PBMCs) are suitable for use) and avoid the logistical difficulties of obtaining B cells from people with active immune responses. Conversely, the power of the ASC-based hmAb approach derives from that very limitation: the approach relies on isolating activated plasmablasts at the peak of the immune response such that the majority of the hmAbs isolated are antigen specific. Thus, although a human vaccine must be available, as well as a donor to receive the vaccination and donate blood, this allows an unprecedented efficiency to generate many specific mAbs. In addition, the process provides a window directly into ongoing immune responses. For example, we have observed expansions of the ASC population during natural infections (unpublished observations). Therefore, it is likely that the procedure can be used to make antibodies from ASCs induced during or soon after natural infections, or to make anti-self antibodies from patients with certain autoimmune disorders. Finally, our method as described herein relies on transient transfection for production of the antibodies, allowing rapid screening of many antibodies but making large-scale antibody preparations difficult. However, should production need to be scaled up, methods of producing stable transfectants and manipulation of the production cell lines could easily be adapted.
The steps intrinsic to our process of producing recombinant hmAbs are a modification of a system that has been used to elucidate basic mechanisms of B-cell immunology and autoimmunity by both us 11, 12 and others 7, 8 . However, the protocol described here is the first integration of this process that yields high-affinity hmAbs specific to an antigen of interest relatively quickly and critically, independent of any specific antigen staining. Thus far, this technique has produced anti-influenza, anti-anthrax toxin antibodies and anti-pneumoccocal hmAbs and can be adapted easily to any immunogen with which humans are vaccinated. For example, another group has generated anti-tetanus antibodies using variable genes from ASCs that were expressed in Escherichia coli 13 . This versatility can provide a library of human antibodies against targets that require a rapid response, such as bioterrorism agents or viral epidemics, or large libraries of hmAbs such as in vaccine evaluation.
Potential applications of the hmAbs produced by vaccinating antigens
There is a common misconception that active immunization precludes the need for passive immunization. Even though a vaccine is necessary to produce antibodies by the method we describe, the monoclonal antibodies produced by our system could be used as passive immunotherapy treatments in a large variety of cases. Pooled human immunoglobulin is currently used as a treatment for several agents, including hepatitis B, tetanus and rabies 14 . Pooled sera carry risks, including potential anaphylactic responses or autoimmune reactions, that could be avoided by a single effective neutralizing monoclonal antibody. Furthermore, in cases of a bioterrorist attack with a pathogen such as anthrax that the general public is not vaccinated against, hmAbs could provide rapid protection against the pathogen while the antibiotics begin to decrease the bacterial load. Similarly, monoclonals against toxins such as botulinum neurotoxin could aid in treating those exposed, as active immunization with vaccine will take at least 2 weeks to confer protection. Finally, there are many immunocompromised populations in which vaccines are ineffective 15 . In these cases, including the elderly and the very young, monoclonal passive immunotherapies could be crucial in treating infectious diseases. A final potential application is for the development of therapeutic antibodies to treat chronic or antibiotic-resistant infectious diseases. Some key examples include the substantial effort now being invested to isolate the rare broadly neutralizing antibodies that can control various strains of HIV 16 . Although these reagents could be used directly as an adjunct to antiviral drugs in controlling viremia, the more important application may be the ability to evaluate many of these antibodies to understand how a vaccine can elicit them. A second example is the potential to generate therapies against antibiotic-resistant bacteria directly from patients that are clearing the infection: new antibiotics are rare, but antibodies can clear these infections despite drug resistance 17 . Neutralizing antibodies from these patients could be used directly or pharmaceutical targeting of the neutralizing epitopes discovered could substantially increase our treatment options. In all of these cases, primarily by the ability to isolate many specific hmAbs rapidly, our technique greatly increases the potential for using monoclonal antibody therapeutics for a wide variety of infectious diseases and bioterrorist agents.
Experimental design
A flow chart briefly describing all stages in this protocol is shown in Figure 1 .
In this protocol, antibody-secreting cells (ASCs) are first isolated from whole blood collected 7 d after vaccination with an immunogen. We have successfully made antibodies following vaccination with Fluvirin (2005 Fluvirin ( -2006 Fluvirin ( , 2006 Fluvirin ( -2007 Fluvirin ( and 2007 Fluvirin ( -2008 , Pneumovax23 and Biothrax. PBMCs are isolated using a standard lymphocyte separation protocol. The frequency of antigen-specific ASCs is analyzed using a standard ELISpot protocol 18 (see Box 1). This assay enumerates the number of IgG-producing ASCs, as well as antigen-specific ASCs. The percentage of antigen-specific, IgGproducing ASCs is a useful measure of the donor's response to the vaccine and therefore the approximate quantity of high-affinity antibodies produced.
The cells are then sorted by flow cytometry. First, the live cell gate, including larger blasting cells, is set using forward versus side scatter. The ASCs are bulk sorted by first gating on CD19 high / CD20 low to neg /CD3 neg and then on CD27 high /CD38 high cells as shown in Figure 2 . The appropriate IgG, IgM and IgD gates are set to obtain IgG-producing ASCs, although it is also possible to use this method to isolate IgM-producing ASCs as well. Finally, the purified ASCs are single cell sorted into single cell PCR plates loaded with catch buffer containing RNase inhibitor.
Using both RT-PCR and nested PCR, the antibody genes in each cell are amplified on a per cell basis. The RT-PCR is accomplished using a cocktail of nine primers, designed to cover all of the families of variable (V) genes possible ( Table 1) . The nested PCR is performed to amplify the DNA enough to obtain sequences of the heavy and light chain V genes. This is necessary for the cloning PCR. In this step, highly specific primers for each V gene family are used to amplify the DNA for cloning. The 'cloning PCR' primers are designed both to incorporate the cloning restriction sites and to place the VDJ heavy or VJ light chain genes in frame with the signal peptide sequences and constant region genes within the respective cloning vectors. Cloning sites were incorporated into the vectors that are specific for the particular heavy or light chain vectors to allow proper, in-frame incorporation of the variable gene inserts. The inserts and vectors are then digested and purified for cloning. The heavy and light chain DNA from each single cell is then cloned into separate vectors and transformed. At least four colonies from the transformation are grown, mini-prepped and sequenced. The sequences from each colony are compared and the colony most closely matching the consensus is then chosen for further amplification to maxi scale.
Transiently transfected human kidney epithelial cells (the HEK293 cell line 19 ) are used to produce the antibody. Polyethyleneimine-based transfection is used with equimolar amounts of heavy and light chain vector according to standard protocols 20 . The cells are allowed to produce antibody for 5 d. The transfection media containing the hmAbs are then purified using protein A agarose beads and concentrated using commercial protein concentrators. During the final stage, the hmAbs are analyzed for concentration, purity and reactivity. . 
PROCEDURE
Lymphoprep and B-cell enrichment TIMING 2 h 1| Collect blood 7 d post-vaccination into acid citric dextrose blood collection tubes (typically 1 for ELISpot, 4 for sort, 40-50 ml of blood total). ! CAUTION Human blood should be considered as infectious and the appropriate safety precautions should be taken. Studies using human subjects should be approved by the appropriate institutional committees.
2| Add RosetteSep at 2.5 ml ml À1 to whole blood. Mix well. m CRITICAL STEP Best results occur if the lymphoprep is begun immediately after collection of the blood but may be done within 18 h of collection. If necessary store blood overnight, store as whole blood at 4 1C and perform lymphoprep immediately prior to staining and cell sorting (in our experience, the ASCs become unstable and die when removed from whole blood and stored overnight or when frozen).
3|
Incubate at room temperature (20-25 1C) for 20 min.
4| Dilute the blood with an equal volume of PBS.
5| Add 15 ml of LSM to a separate 50-ml conical tube. Carefully layer diluted blood over the LSM. Layer no more than 30 ml of diluted blood over 15 ml of LSM. Use multiple tubes if necessary.
6| Centrifuge for 30 min at 800g at room temperature with no brake.
7| After centrifugation, the enriched PBMCs will form a band at the interface between the serum and the LSM. Remove this band with a Pasteur pipette and transfer to a new 50-ml centrifuge tube.
8| Rinse the enriched PBMCs by diluting to 50 ml with PBS, centrifuge for 5-10 min at 800g at room temperature with no brake, then remove the supernatant. 9| If using more than one tube, combine the cells. Repeat Step 8, decreasing the centrifugation speed to 360g. Brake may be used. 11| If the cells appear bloody (i.e., contain significant amounts of red blood cells), clear with ACK buffer (add 1 ml of ACK for 1-2 min). Wash the cells twice with PBS. Filter the cells through a 40-mm cell strainer to remove clumps.
Staining and flow cytometry TIMING

12|
Resuspend approximately 3 million cells in 100 ml of staining buffer; these are the cells that will be used for sorting. In addition, prepare one aliquot of cells (B0.5 Â 10 6 cells in 100 ml of staining buffer) for each fluorophore to be tested in Step 13 and one aliquot of cells that will remain unstained. These compensation controls will be used to adjust the sensitivity of the flow cytometer detectors to avoid overlap of the emission spectra when the various flourophores are combined. m CRITICAL STEP All buffers for staining should contain 2% FCS (vol/vol) in PBS to block nonspecific staining. m CRITICAL STEP The specific amounts of each antibody used should be titrated to give distinct single color populations before setting up a new experiment. Appropriate species-specific isotype control antibodies should be used to distinguish specifically stained populations from any background staining that might occur.
14| Incubate the cells for 30 min at 4 1C.
15| Wash twice with 200 ml of 2% FCS in PBS.
16| Add 1:500 Streptavidin PE-Cy7 and incubate for 20 min at 4 1C.
17| Wash twice again; pass the cells through another cell strainer to avoid clogs in the cytometer.
18|
Gate the cells as shown in the strategy in Figure 2 (CD19 + /CD20 À /CD3 À /CD27 high /CD38 high ). Alternatively, the gating scheme illustrated in Figure 1 has also been used without affecting the isolation of specific ASCs. ASCs are then further enriched based on IgG or any other isotype desired.
19| Bulk sort the cells into tubes containing 2% FCS in PBS buffer collecting the cells gated as above.
? TROUBLESHOOTING 20| Re-sort the cells on forward versus side scatter (live cell gate with doublet discrimination) into single cell PCR plates containing 10 ml of RNase-inhibiting RT-PCR catch buffer. To facilitate the RT-PCR step, sort only into half of the plate and do not put cells in Row H (catch buffer should be added to this row to allow for PCR negative controls). Immediately seal each plate with a microseal foil label and place on dry ice until the cell sorting is finished when plates can be placed in a À80 1C freezer. m CRITICAL STEP Use RNase-free precautions for Step 20. As the catch buffer is hypotonic, the cells are lysed, and with immediate freezing, their RNA is protected by the included RNase inhibitor. m CRITICAL STEP It is necessary to use multiple buffer controls (row H) because the likelihood of PCR contamination increases substantially with the many cycles of PCR required to amplify the variable genes from single B cells. ' PAUSE POINT Plates may be stored for months to several years if they are immediately flash frozen on dry ice after the collection and kept at À80 1C. Do not use the 'Q' solution. The primers for the master mix have been previously published 7, 8 and are used from 0.6 mM stocks (see Table 1 22| Carefully add 15 ml of the master mix to each well of the plate and then carefully apply dome lids to the plate. 
23|
Prepare the nested PCR master mixes: 24 ml for each well (1.2 ml for half a plate) as described in the table below. One master mix is necessary for the light chain and one mix is necessary for the VH3 family heavy chain. The VH3 primer will amplify VH genes from most other families as well. For completeness, a separate VH1/5 and VH4 nested PCR may be done as well (see Table 1 for primers), though in our experience these reactions identify the variable genes of most cells if performed separately. 25| Centrifuge the nested plates briefly and run 2 ml of each well on a 1% agarose gel (wt/vol). Positive results are determined by the visualization of a band at approximately 400 bp. Purify positive products with the QIAquick PCR Microcentrifuge Protocol, eluting with 40 ml of EB buffer.
? TROUBLESHOOTING 26| Sequence each purified well using a mixture of the VH3a and VH3b primers (or the VH1/5 or VH4 primers as appropriate) for the heavy products or PanVk or cloning-PCR Vl primers for the kappa or lambda products, respectively. Use of the variable gene-specific (5¢) primers for sequencing helps to ensure identification of the J portion of the heavy chain VDJ or light chain VJ genes that is important for the cloning PCR in Step 27. Variable and junctional (J) gene segments can be identified using the immunoglobulin BLAST search engine at the NCBI website (http://www.ncbi.nlm.nih.gov/igblast/).
27| Prepare the cloning PCR master mixes as detailed in the table below. To ensure that the master mix is not contaminated, prepare each master mix with enough volume to have one buffer control (see Table 1 'Cloning PCR' primers). Many of the primers for the cloning PCR are used for several gene families as they prime conserved sequences. The targeted gene segments are all indicated in the name of the primer in Table 1 . For example, the 5¢ AgeI VH1/5/7 primer is used for any gene from the VH1, VH5 or VH7 families; the 5¢ AgeI VH3-9/30/33 primer is used for either VH3-9, VH3-30 or VH3-33 genes; the 3¢ BsiWI Jk 1/2/4 primer is used for either Jk 1, Jk 2 or Jk 4. 28| Add 1 ml of the RT product to each 24 ml of cloning PCR mix and apply dome caps as in Step 22. Products should be checked on a gel to ensure that a band is present and that the controls are not contaminated as described in Step 25. Run the PCR using the following conditions: 95 1C for 4 min, 35 cycles of 95 1C for 1 min, 57 1C for 1 min and 72 1C for 1.5 min.
PCR purification TIMING 10 min 29| Follow the protocol outlined in the QIAquick PCR Microcentrifuge Protocol with one exception: to elute the DNA, apply 31 ml of PCR water to the column, let the column sit for 1 min and then centrifuge. For all centrifuging steps, centrifuge for 60 s at B17,900g at room temperature as per Qiagen protocol.
' PAUSE POINT PCR products may be stored for up to 1 month at À20 1C.
First digestion of gamma, kappa or lambda chain variable gene inserts TIMING 5-20 h 30| For all inserts: add 3.5 ml of NEB buffer 1 and 1 ml of AgeI to purified PCR products.
31|
Mix the sample by pipetting up and down.
32| Overlay the sample with 40 ml of sterile mineral oil.
33|
Incubate the samples for 4 h or overnight in a 37 1C water bath or heat block.
Digestion purification TIMING 10 min 34| Purify using the same protocol as the 'PCR purification' in Step 29.
Second digestion TIMING 5-20 h 35| For a gamma chain insert, add 3.5 ml NEB buffer 3, 0.35 ml BSA and 1 ml SalI to the purification product. For a kappa chain insert, add 3.5 ml NEB buffer 3 and 1 ml BsiWI to the purification product. For a lambda chain insert, add 3.5 ml NEB buffer 2, 0.35 ml BSA and 1 ml XhoI to the purification product.
36| Overlay the sample with 40 ml of sterile mineral oil.
37|
Incubate the sample for 4 h or overnight in a water bath. For kappa inserts, incubate at 55 1C. For gamma and lambda inserts, incubate at 37 1C.
Gel purification TIMING 1 h 38| Run all samples on a 1% agarose gel (wt/vol). The insert band will be approximately 400 bp in length.
39| Follow the protocol outlined in the QIAquick Gel Extraction Kit (using a microcentrifuge) with one exception: to elute the DNA, apply 34 ml of EB buffer to the column, let the column sit for 1 min and centrifuge. Note: all centrifuge steps are carried out for 60 s. ' PAUSE POINT After excising the insert band from the gel, you may store it at 4 1C overnight before proceeding with the remaining gel purification protocol. The final product may be stored for up to 1 year at À20 1C.
Ligation TIMING 2.5-18 h 40|
Vector and insert DNA concentrations should be calculated from the A 260 reading of a spectrophotometer (an A 260 of 1.0 is 50 mg ml À1 of pure double stranded DNA). A five-fold molar excess of insert to vector should be used. As the vector is approximately 5,700 bp and the insert is typically 350-400 bp (variance is due to the CDR3 junction), a 3:1 ratio of vector to insert can be used.
41| Add 1 ml of vector (from a 1 mg ml À1 stock), 1 ml of T4 DNA ligase buffer, 1 ml of T4 ligase and an appropriate volume of the insert purification product to equal 0.3 mg into a clean 0.5-ml tube.
42| Add PCR water to a final volume of 10 ml. Incubate the sample overnight at 16 1C in a PCR machine or for 2 h at room temperature.
Transformation of DH5a cells TIMING 3 d
43| Follow the protocol included with the DH5a cells with the following exceptions: use 25 ml of DH5a cells and 3 ml of DNA, and plate the cells on an LB plate containing 50 mg ml À1 of ampicillin. Incubate the cultures for 2-3 h in SOC media at 37 1C, and plate 100 ml of the transformation culture. Incubate the plates overnight at 37 1C.
44| Choose four colonies from the plate to ensure a consensus variable gene sequence is identified. For each colony, inoculate one 14-ml round-bottom tube containing 5 ml of LB broth and ampicillin (50 mg ml À1 ). 46| Make glycerol stocks of each culture by transferring 300 ml of 1:1 sterile LB/glycerol and 700 ml of the confluent culture to a 2-ml tube, mix well and freeze at À80 1C. These glycerol stocks are still viable after several years at À80 1C.
45|
Miniprep TIMING 45-60 min 47| Pellet bacteria by centrifuging the culture tubes (prepared in Steps 44 and 45) for 10 min at 800g. Discard the supernatant.
48| Follow the protocol outlined in the QIAprep Spin Miniprep Kit Handbook (using a microcentrifuge) with one exception: elute the DNA with 40 ml of EB buffer. Note: all centrifuge steps are carried out for 60 s.
49| Sequence the eluted DNA with the AbVec primer (see Table 1 ).
Maxiprep TIMING Z34 h 50| Compare the four mini-prep sequences using DNA sequence alignment software (Such as ClustalW: http://www.ebi.ac.uk/ Tools/clustalw2/index.html). It is expected that some sequences will have accumulated base exchanges due to PCR errors but one of the four samples typically represents the consensus.
? TROUBLESHOOTING 51| With a scraping from the glycerol stock of the colony of choice, inoculate one 14-ml round-bottom tube containing 5 ml of LB broth with ampicillin (50 mg ml À1 ).
52|
Incubate the tubes for 4-5 h, shaking at 225 r.p.m. on an orbital shaker, at 37 1C.
53|
Transfer the cultures to 500-ml flasks containing 250 ml of LB broth and ampicillin (50 mg ml À1 ). Incubate the flasks overnight, shaking at 225 r.p.m. on an orbital shaker, at 37 1C.
54| Follow the protocol outlined in the Genopure Plasmid Maxi Kit with the following exception: re-dissolve the plasmid DNA pellet in 400 ml of pre-warmed (50 1C) elution buffer. 56| Warm DMEM media to room temperature; thaw PEI solution, heavy chain and light chain DNA.
57|
For each plate to be transfected, aliquot 2.4 ml of DMEM into a conical vial. Add 9 mg of heavy chain DNA and 9 mg of light chain DNA per plate to the DMEM.
58| Add 100 ml of PEI solution per plate to the prepared DMEM and DNA mixture. Immediately vortex. Incubate at room temperature for 15 min.
59| Remove all but 18 ml of the culture media from each plate to be transfected.
60| Gently add 2.5 ml of PEI mixture to each plate, rocking the plate to ensure even distribution.
61| Incubate the cells with the PEI mixture in an incubator at 37 1C with 5% CO 2 for 24 h.
62|
Change the culture media to basal media (20-25 ml per plate).
63| Collect the media from the plates 4 d later.
' PAUSE POINT The supernatant may be stored at 4 1C for several months if NaN 3 is added at a concentration of 0.05% (wt/vol). For some applications (i.e., ELISA), the antibody-containing supernatant is sufficient for testing the mAbs and the protein purification steps (Steps 64-77) can be optional. However, for long-term storage and more flexibility as typical of our applications, we always purify the antibodies.
Protein purification TIMING 7-24 h 64| Prepare protein A agarose beads by adding approximately 1.5 ml of suspended beads to 50 ml of PBS in a 50-ml conical tube.
65| Centrifuge the tubes of beads for 10 min at 2,100g at room temperature with no brake. Remove the PBS with an aspirator.
m CRITICAL STEP Do not use brake on any of the centrifugations involving the agarose beads, as braking can damage the beads. Even slight breaking at the end of the spin can cause the beads to fluff, making it difficult to cleanly remove the supernatant.
66| Rinse each tube of beads with PBS (fill each tube with 50 ml of PBS and repeat Step 65).
67| Centrifuge the media collected from the transfection for 10 min at 900g at room temperature, and then transfer the media from two plates (25 ml from each plate) to each tube of beads.
68| Incubate the media with the beads for 1-2 h at room temperature or overnight at 4 1C with slow agitation using a variable speed angle rocker. It works well to stabilize the tubes in a horizontal position.
69| Centrifuge the tubes of beads for 10 min at 2,100g at room temperature with no brake. Remove the media with an aspirator.
70| Add 35 ml of 1 M NaCl to each tube. Centrifuge the tubes of beads for 10 min at 2,100g at room temperature with no brake. Remove the 1 M NaCl with an aspirator. 76| Transfer the neutralized sample to the top of an amicon protein concentrator; add PBS to a final volume of 15 ml. Centrifuge the concentrator for 8-12 min at 2,100g at room temperature with brake on, until a volume of 0.5-1 ml is reached.
77|
Transfer the concentrated antibody sample from the concentrator into a clean 1.5-ml tube. If desired, preserve the antibody by adding NaN 3 to 0.05% (wt/vol). Note that biological assays using live cells (i.e., viral infection neutralization assays) are sensitive to NaN 3 .
78|
To reuse the beads (up to 10 times as suggested by the manufacturer), add 15 ml of 0.1 M glycine-HCl to each tube of beads after 3-5 ml containing the antibody fraction is removed. Incubate on a tabletop shaker for 30 min, centrifuge for 10 min at 2,100g at room temperature with no brake, remove the glycine-HCl with an aspirator, then rinse twice with PBS (according to Step 89). Store in conical vials with 50 ml of PBS containing 0.05% NaN 3 at 4 1C for up to 6 months.
Protein quantification TIMING 2-3 h 79| Follow the protocol included with the EZQ Protein Quantification Kit with the following exception: stain the paper for 60 min. Protein concentrations can be checked using an alternative quantification method, such as anti-IgG ELISA assays relative to a good IgG standard, the Qubit Protein Quantification Kit or a spectrophotometer. For critical applications, we typically verify the concentrations by more than one method. ? TROUBLESHOOTING Gel confirmation of protein quality TIMING 5 h 80| Run the resulting purified antibodies on an SDS-PAGE gel (12% gel (vol/vol), 4% stacking (vol/vol), reducing conditions). The resulting bands for heavy chain will be between 50 and 60 kDa and the light chain will be between 20 and 25 kDa, see Step 79, protein quantification: 2-3 h
Step 80, protein qualification: 5 h *Assumes overnight turnaround on DNA sequencing or synchronization of clones processed so that sequencing delays are avoided.
? TROUBLESHOOTING Troubleshooting advice can be found in Table 2 . Poor or unusual response to vaccine Use the specified gating strategy to collect the ASCs that are present
Step 22: Negative controls (wells with no cells) on RT/nested PCR have a positive band Contamination Plates will probably have to be discarded
Step 25: Negative controls on cloning PCR have a positive band Contamination Repeat cloning PCR for contaminated reactions
Step 50: A portion of miniprepped colonies do not contain the insert or there are mutations so that no consensus is found from the four picked colonies PCR-introduced errors are not uncommon with the large number of PCR cycles required for single-cell PCR Pick four more colonies from the plate, miniprep and sequence until there are enough sequences to establish a consensus
Step 79: After transfection, the concentration of antibody produced is very low (less than 50 mg ml À1 )
Beads have reached capacity or the particular antibody is a 'poor' expresser. It is clear that not all mAbs will be expressed in abundance Run transfection media from which the antibody has been purified on a protein gel. If antibody bands are still present, discontinue the use of that set of beads and purify the supernatant again with a new set. Otherwise, more transfections may be required
Plates not confluent enough or cells have been passaged for too long Run transfection media from which the antibody has been purified on a protein gel. If antibody bands are not present, transfect again, checking confluency of plate. Some antibodies do not transfect well; in such cases, transfect eight or more plates instead of four ASC, antibody-secreting cell.
